27940380|t|Biomimetic biodegradable artificial antigen presenting cells synergize with PD-1 blockade to treat melanoma
27940380|a|Biomimetic materials that target the immune system and generate an anti-tumor responses hold promise in augmenting cancer immunotherapy. These synthetic materials can be engineered and optimized for their biodegradability, physical parameters such as shape and size, and controlled release of immune-modulators. As these new platforms enter the playing field, it is imperative to understand their interaction with existing immunotherapies since single - targeted approaches have limited efficacy. Here, we investigate the synergy between a PLGA -based artificial antigen presenting cell (aAPC) and a checkpoint blockade molecule, anti-PD1 monoclonal antibody (mAb). The combination of antigen - specific aAPC -based activation and anti-PD-1 mAb checkpoint blockade induced the greatest IFN-γ secretion by CD8+ T cells in vitro. Combination treatment also acted synergistically in an in vivo murine melanoma model to result in delayed tumor growth and extended survival, while either treatment alone had no effect. This was shown mechanistically to be due to decreased PD-1 expression and increased antigen - specific proliferation of CD8+ T cells within the tumor microenvironment and spleen. Thus, biomaterial -based therapy can synergize with other immunotherapies and motivates the translation of biomimetic combinatorial treatments.
27940380	0	10	Biomimetic	T073	C1136386
27940380	11	24	biodegradable	T169	C0220796
27940380	25	35	artificial	T073	C2936320
27940380	36	60	antigen presenting cells	T025	C0003315
27940380	61	70	synergize	T080	C0205195
27940380	76	89	PD-1 blockade	T121	C3883362
27940380	93	98	treat	T169	C1522326
27940380	99	107	melanoma	T191	C0025202
27940380	108	128	Biomimetic materials	T073	C1136386
27940380	134	140	target	T169	C1521840
27940380	145	158	immune system	T022	C0020962
27940380	175	195	anti-tumor responses	T042	C1516031
27940380	212	222	augmenting	T081	C0205217
27940380	223	243	cancer immunotherapy	T061	C0278348
27940380	251	270	synthetic materials	T073	C0440251
27940380	278	288	engineered	T052	C0441655
27940380	293	302	optimized	T052	C0441655
27940380	313	329	biodegradability	T169	C0220796
27940380	331	350	physical parameters	T033	C0449381
27940380	359	364	shape	T082	C0332479
27940380	369	373	size	T082	C0456389
27940380	379	397	controlled release	T079	C0868939
27940380	401	418	immune-modulators	T121,T129	C0005525
27940380	433	442	platforms	T075	C1710360
27940380	505	516	interaction	T169	C1704675
27940380	531	546	immunotherapies	T061	C0021083
27940380	553	559	single	T081	C0205171
27940380	562	581	targeted approaches	T061	C2985566
27940380	587	594	limited	T169	C0439801
27940380	595	603	efficacy	T080	C1280519
27940380	614	625	investigate	T169	C1292732
27940380	630	637	synergy	T169	C0205245
27940380	648	652	PLGA	T109,T122	C0071599
27940380	660	670	artificial	T073	C2936320
27940380	671	694	antigen presenting cell	T025	C0003315
27940380	696	700	aAPC	T025	C0003315
27940380	708	727	checkpoint blockade	T043	C3544497
27940380	728	736	molecule	T167	C0567416
27940380	738	772	anti-PD1 monoclonal antibody (mAb)	T116,T121,T129	C4289970
27940380	778	789	combination	T080	C0205195
27940380	793	800	antigen	T129	C0003320
27940380	803	811	specific	T080	C0205369
27940380	812	816	aAPC	T025	C0003315
27940380	824	834	activation	T043	C1326120
27940380	839	852	anti-PD-1 mAb	T116,T121,T129	C4289970
27940380	853	872	checkpoint blockade	T043	C3544497
27940380	873	880	induced	T169	C0205263
27940380	894	909	IFN-γ secretion	T043	C3156720
27940380	913	925	CD8+ T cells	T025	C0242629
27940380	926	934	in vitro	T080	C1533691
27940380	936	957	Combination treatment	T061	C0009429
27940380	969	984	synergistically	T080	C2986495
27940380	991	998	in vivo	T082	C1515655
27940380	999	1005	murine	T109,T121	C0591833
27940380	1006	1014	melanoma	T191	C0025202
27940380	1015	1020	model	T170	C3161035
27940380	1034	1041	delayed	T079	C0205421
27940380	1042	1054	tumor growth	T191	C0598934
27940380	1068	1076	survival	T169	C0220921
27940380	1091	1100	treatment	T061	C0087111
27940380	1111	1120	no effect	T080	C1301751
27940380	1166	1175	decreased	T081	C0205216
27940380	1176	1180	PD-1	T121	C3883362
27940380	1181	1191	expression	T045	C0597360
27940380	1196	1205	increased	T081	C0205217
27940380	1206	1213	antigen	T129	C0003320
27940380	1216	1224	specific	T080	C0205369
27940380	1225	1238	proliferation	T043	C0596290
27940380	1242	1254	CD8+ T cells	T025	C0242629
27940380	1266	1288	tumor microenvironment	T070	C2936626
27940380	1293	1299	spleen	T023	C0037993
27940380	1307	1318	biomaterial	T122	C0005479
27940380	1326	1333	therapy	T061	C0087111
27940380	1338	1347	synergize	T080	C0205195
27940380	1359	1374	immunotherapies	T061	C0021083
27940380	1408	1418	biomimetic	T073	C1136386
27940380	1419	1443	combinatorial treatments	T061	C0009429